Papers
36
Total Citations
939
H-Index
16
About
Dr. Mark L. Gonzalgo is a leading urologic oncologist whose research has fundamentally shaped the modern surgical management of urologic cancers, particularly through rigorous comparisons of robotic, laparoscopic, and open surgical techniques. His work is centered on optimizing oncologic outcomes, functional recovery, and quality of life for patients with bladder, prostate, and upper tract urothelial cancers. Dr. Gonzalgo was a principal investigator in the landmark RAZOR trial, the first randomized study to demonstrate non-inferior 3-year progression-free survival for robotic versus open radical cystectomy for bladder cancer, a finding with over 115 citations that has influenced global practice. He has also made seminal contributions to prostate cancer surgery, publishing highly cited comparative effectiveness studies on open, laparoscopic, and robotic prostatectomy using validated quality-of-life metrics. As a founding member of the multi-institutional ROBUUST collaborative, he has led large-scale analyses on nephroureterectomy and lymph node dissection for upper tract tumors. With over 500 cumulative citations across his most influential works, Dr. Gonzalgo’s research provides the highest level of evidence guiding surgical decision-making in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7Robotic surgical training of the urologic oncologist54 citations · 2009
- 8
- 9
- 10